Segall Bryant & Hamill LLC Sells 1,679 Shares of Stryker Corporation $SYK

Segall Bryant & Hamill LLC lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 3.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,021 shares of the medical technology company’s stock after selling 1,679 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Stryker were worth $19,600,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Stryker by 0.8% in the third quarter. Vanguard Group Inc. now owns 33,773,399 shares of the medical technology company’s stock worth $12,485,012,000 after acquiring an additional 272,828 shares in the last quarter. State Street Corp lifted its holdings in shares of Stryker by 1.0% in the 2nd quarter. State Street Corp now owns 14,956,732 shares of the medical technology company’s stock worth $5,929,765,000 after purchasing an additional 150,204 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Stryker by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock worth $2,910,445,000 after purchasing an additional 79,654 shares in the last quarter. Alliancebernstein L.P. grew its position in Stryker by 307.6% in the 2nd quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock valued at $2,214,146,000 after purchasing an additional 4,223,366 shares during the period. Finally, Norges Bank bought a new stake in Stryker during the 2nd quarter valued at $1,882,173,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of NYSE SYK opened at $384.06 on Wednesday. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $404.87. The stock’s 50 day moving average price is $364.38 and its 200-day moving average price is $369.17. The company has a market capitalization of $146.98 billion, a PE ratio of 45.72, a PEG ratio of 2.26 and a beta of 0.85. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. During the same period last year, the business posted $4.01 earnings per share. Stryker’s revenue was up 11.4% on a year-over-year basis. On average, equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s payout ratio is 41.90%.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Sanford C. Bernstein raised their price objective on shares of Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Evercore set a $390.00 target price on shares of Stryker in a report on Monday, January 5th. Citigroup reaffirmed a “market outperform” rating on shares of Stryker in a research report on Friday, January 30th. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, BTIG Research increased their price objective on Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Thirteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $426.47.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.